A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Metastatic Urothelial Carcinoma · Urothelial Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 390 (planned)
- Started
- Jun 23, 2023
- Main results expected
- May 31, 2027
- Fully finished
- May 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Objective Response Rate (ORR)
Measured over: Up to ~4 years
Part 1: Percentage of Participants experiencing an Adverse Event (AE)
Measured over: Up to ~4 years
Part 1: Percentage of Participants who Discontinue study interventions due to an AE
Measured over: Up to ~4 years
Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)
Measured over: Up to 21 days
Part 2: Progression Free Survival (PFS)
Measured over: Up to ~4 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05845814 · record last updated 2025-09-10 · checked 2026-11-09 15:47 UTC